INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
08 févr. 2023 08h45 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
11 févr. 2019 08h00 HE
|
INmune Bio, Inc.
The Alzheimer’s Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer’s Disease LA JOLLA, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- INmune...